Novartis' psoriasis drug yields positive results in late-stage trial

07/9/2013 | Reuters

Novartis' secukinumab worked better than Amgen's Enbrel in clearing the skin of people with moderate to severe plaque-type psoriasis in a Phase III trial. Novartis plans to submit the drug for regulatory review by year-end.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ